INNV vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
INNV exhibits a stable financial foundation with a Piotroski F-Score of 6/9, but it is currently suffering from a severe valuation disconnect. The current price of $8.20 trades at a massive premium to both the Graham Number ($1.46) and the growth-based Intrinsic Value ($0.35). While the forward P/E of 24.12 suggests a significant earnings recovery is expected, the trailing P/E of 164.00 and thin profit margins (0.71%) indicate the stock is priced for perfection. Combined with bearish insider sentiment and a technical trend of 0/100, the risk-to-reward ratio is unfavorable.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
INNV vs MRK: Head-to-Head Comparison
This page compares InnovAge Holding Corp. (INNV) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.